MCID: INF023
MIFTS: 57

Inflammatory Breast Carcinoma

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Inflammatory Breast Carcinoma

MalaCards integrated aliases for Inflammatory Breast Carcinoma:

Name: Inflammatory Breast Carcinoma 12 15 73
Inflammatory Breast Cancer 76 53 55
Inflammatory Carcinoma of Breast 12
Inflammatory Breast Neoplasms 44
Breast Cancer, Inflammatory 53
Mastitis Carcinomatosa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6263
MeSH 44 D058922
NCIt 50 C4001
UMLS 73 C0278601

Summaries for Inflammatory Breast Carcinoma

NIH Rare Diseases : 53 Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin of the breast. This type of breast cancer is called �??inflammatory�?� because the breast often looks swollen and red, or �??inflamed.�?� The skin may also look dimpled like the skin of an orange. IBC can be difficult to diagnose because there is no lump to feel or detect on a mammogram. It is crucial to identify IBC right away because early diagnosis and treatment can greatly improve the outcome. Patients are often given a combination of treatments, including chemotherapy, surgery, and radiation therapy. Approximately one-third of individuals diagnosed with IBC will become long-term survivors. Like other types of breast cancer, IBC can occur in men, but usually at an older age than in women. Some studies have shown an association between family history of breast cancer and IBC, but more studies are needed to draw firm conclusions.

MalaCards based summary : Inflammatory Breast Carcinoma, also known as inflammatory breast cancer, is related to ovarian cancer 1 and adenocarcinoma, and has symptoms including edema, pain and peau d'orange. An important gene associated with Inflammatory Breast Carcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Pathways in cancer. The drugs Fluorouracil and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and prostate, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased viability with paclitaxel

Disease Ontology : 12 A breast adenocarcinoma that is characterized by the clinical appearance of inflammation, with edema and redness of the breast due to pathologic plugging of the dermal lymphatics of the breast with tumor emboli.

Wikipedia : 76 Inflammatory breast cancer is one of the most aggressive types of breast cancer that can occur in women... more...

Related Diseases for Inflammatory Breast Carcinoma

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ

Diseases related to Inflammatory Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 1 29.6 CDH1 ERBB2
2 adenocarcinoma 29.5 CDH1 EGFR ERBB2
3 squamous cell carcinoma 29.5 CDH1 EGFR ERBB2
4 fallopian tube carcinoma 29.3 ERBB2 ESR1 PGR
5 ovarian cancer 29.2 CDH1 EGFR ERBB2 ESR1 PGR
6 breast cystic hypersecretory carcinoma 10.1 CDH1 ERBB2
7 peritoneal mesothelioma 10.1 EGFR ESR1
8 comedo carcinoma 10.1 ERBB2 ESR1
9 laryngeal disease 10.1 CDH1 EGFR
10 oropharynx cancer 10.1 CDH1 EGFR
11 pharynx cancer 10.1 CDH1 EGFR
12 bronchiolo-alveolar adenocarcinoma 10.1 CDH1 EGFR
13 breast intraductal proliferative lesion 10.1 EGFR ERBB2
14 tonsil cancer 10.1 CDH1 ERBB2
15 lymphoma 10.0
16 mastitis 10.0
17 breast squamous cell carcinoma 10.0 EGFR ERBB2
18 vestibular gland benign neoplasm 10.0 ESR1 PGR
19 bartholin's gland adenoma 10.0 ESR1 PGR
20 vulvar syringoma 10.0 ESR1 PGR
21 lung leiomyoma 10.0 ESR1 PGR
22 myoma 10.0 ESR1 PGR
23 vulvar benign neoplasm 10.0 ESR1 PGR
24 acneiform dermatitis 10.0 EGFR ERBB2
25 trigonitis 10.0 ESR1 PGR
26 vulvar leiomyoma 10.0 ESR1 PGR
27 predominantly cortical thymoma 10.0 ESR1 PGR
28 bartholin's gland benign neoplasm 10.0 ESR1 PGR
29 progesterone resistance 10.0 ESR1 PGR
30 endometrial squamous cell carcinoma 10.0 ESR1 PGR
31 mucinous lung adenocarcinoma 10.0 EGFR ERBB2
32 cribriform carcinoma 10.0 ESR1 PGR
33 endometrial mucinous adenocarcinoma 10.0 ESR1 PGR
34 adenoid basal cell carcinoma 10.0 ESR1 PGR
35 peritoneal benign neoplasm 10.0 ESR1 PGR
36 gastric signet ring cell adenocarcinoma 10.0 CDH1 PGR
37 gender identity disorder 10.0 ESR1 PGR
38 deep angioma 10.0 ESR1 PGR
39 diffuse peritoneal leiomyomatosis 10.0 ESR1 PGR
40 leiomyomatosis 10.0 ESR1 PGR
41 gallbladder adenocarcinoma 10.0 EGFR ERBB2
42 synchronous bilateral breast carcinoma 10.0 ESR1 PGR
43 female reproductive endometrioid cancer 10.0 ESR1 PGR
44 cervical carcinosarcoma 10.0 ESR1 PGR
45 estrogen excess 10.0 ESR1 PGR
46 adenosquamous lung carcinoma 10.0 EGFR ERBB2
47 intramuscular hemangioma 10.0 ESR1 PGR
48 colonic disease 10.0 CDH1 EGFR ESR1
49 glycogen-rich clear cell breast carcinoma 10.0 ESR1 PGR
50 mammographic density 10.0 ESR1 PGR

Graphical network of the top 20 diseases related to Inflammatory Breast Carcinoma:



Diseases related to Inflammatory Breast Carcinoma

Symptoms & Phenotypes for Inflammatory Breast Carcinoma

UMLS symptoms related to Inflammatory Breast Carcinoma:


edema, pain, peau d'orange

GenomeRNAi Phenotypes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.43 CDH1 ERBB2 ESR1 FUT3 PGR PROX1
2 Decreased viability with paclitaxel GR00179-A-1 8.8 EGFR ERBB2
3 Decreased viability with paclitaxel GR00179-A-3 8.8 EGFR

MGI Mouse Phenotypes related to Inflammatory Breast Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 CDH1 EGFR ERBB2 ESR1 PGR PROX1
2 cellular MP:0005384 9.95 CDH1 EGFR ERBB2 ESR1 PGR PROX1
3 endocrine/exocrine gland MP:0005379 9.88 CDH1 EGFR ERBB2 ESR1 PGR PROX1
4 digestive/alimentary MP:0005381 9.85 CDH1 EGFR ERBB2 ESR1 PROX1
5 embryo MP:0005380 9.83 CDH1 EGFR ERBB2 ESR1 PGR
6 integument MP:0010771 9.77 CDH1 EGFR ERBB2 ESR1 PGR
7 muscle MP:0005369 9.65 EGFR ERBB2 ESR1 PGR PROX1
8 limbs/digits/tail MP:0005371 9.62 EGFR ERBB2 ESR1 PGR
9 neoplasm MP:0002006 9.55 CDH1 EGFR ERBB2 ESR1 PGR
10 normal MP:0002873 9.43 CDH1 EGFR ERBB2 ESR1 PGR PROX1
11 reproductive system MP:0005389 9.02 CDH1 EGFR ERBB2 ESR1 PGR

Drugs & Therapeutics for Inflammatory Breast Carcinoma

Drugs for Inflammatory Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
4
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
5
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
6
leucovorin Approved Phase 3 58-05-9 6006 143
7
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
8
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
9
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
11
Pertuzumab Approved Phase 3,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
12
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 154361-50-9 60953
13
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
14
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
15
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 135968-09-1
16
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
17
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 180288-69-1 9903
18
Goserelin Approved Phase 2, Phase 3,Phase 3 65807-02-5 47725 5311128
19
Aprepitant Approved, Investigational Phase 3 170729-80-3 6918365 151165
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 1177-87-3
21
Prochlorperazine Approved, Vet_approved Phase 3 58-38-8, 1984-02-6 4917
22
Fosaprepitant Approved Phase 3 172673-20-0 219090
23
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
24
Palonosetron Approved, Investigational Phase 3 119904-90-4, 135729-61-2, 135729-56-5 148211
25
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 50-02-2 5743
27
Adenosine Approved, Investigational Phase 3 58-61-7 60961
28
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
29
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
30
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 657181 3911
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
32
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
33
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
34
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1 388082-78-8, 231277-92-2 208908 9941095
35
Substance P Investigational Phase 3 33507-63-0 44359816
36 Estrogens Phase 3,Phase 2,Phase 1
37 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Vitamin B9 Phase 3
39 Folate Phase 3
40 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Antimetabolites Phase 3,Phase 2,Phase 1
43 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
44 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1
45 Folic Acid Antagonists Phase 3
46 Citrate Phase 3,Phase 2
47 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1
48 Estrogen Antagonists Phase 3,Phase 2,Phase 1
49 Vitamin B Complex Phase 3
50 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer Unknown status NCT00003680 Phase 3 CMF regimen;cyclophosphamide;fluorouracil;methotrexate;tamoxifen citrate;thiotepa
2 Combination Chemotherapy in Treating Women With Breast Cancer Unknown status NCT00003679 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;tamoxifen citrate
3 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Unknown status NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
4 Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer Unknown status NCT00397761 Phase 2, Phase 3 capecitabine;paclitaxel albumin-stabilized nanoparticle formulation
5 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
6 Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Completed NCT02324088 Phase 3 Docetaxel;Cyclophosphamide;Epirubicin
7 Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer Completed NCT00017095 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
8 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
9 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
10 S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00016406 Phase 3 cyclophosphamide;doxorubicin;paclitaxel
11 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
12 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed NCT00475085 Phase 3 aprepitant;dexamethasone;granisetron hydrochloride;palonosetron hydrochloride;prochlorperazine;placebo
13 A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed NCT02131064 Phase 3 Carboplatin;Docetaxel;Pertuzumab;Trastuzumab;Trastuzumab Emtansine
14 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
15 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
16 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Active, not recruiting NCT02003209 Phase 3 Aromatase Inhibition Therapy;Carboplatin;Docetaxel;Goserelin Acetate
17 Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Terminated NCT00016276 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;cyclophosphamide;paclitaxel;tamoxifen citrate
18 Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy Terminated NCT00028704 Phase 3
19 Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery Unknown status NCT00251329 Phase 2 neoadjuvant chemotherapy
20 A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early Unknown status NCT00957125 Phase 2 Epirubicin;Docetaxel;Bevacizumab
21 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
22 Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer Unknown status NCT00002627 Phase 1, Phase 2 carboplatin;cyclophosphamide;mesna;paclitaxel
23 Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Unknown status NCT00398489 Phase 2 anastrozole;cyclophosphamide;docetaxel;epirubicin hydrochloride;goserelin acetate;tamoxifen citrate
24 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed NCT00558103 Phase 2 lapatinib;Pazopanib
25 Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer Completed NCT00105950 Phase 2 lapatinib
26 Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer Completed NCT00066443 Phase 1, Phase 2 docetaxel;epirubicin hydrochloride
27 Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer Completed NCT00016549 Phase 2
28 Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer Completed NCT01325428 Phase 2 Afatinib once daily (OD);Vinorelbine Weekly
29 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193050 Phase 2 Gemcitabine;Epirubicin;Docetaxel
30 Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer Completed NCT00111787 Phase 2 Lapatinib;Paclitaxel
31 Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Completed NCT00193206 Phase 2 Gemcitabine;Epirubicin;Albumin-bound Paclitaxel
32 Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Completed NCT02199418 Phase 2 Paclitaxel;Cisplatin
33 Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer Completed NCT01206881 Phase 2 pegylated liposomal doxorubicin
34 Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Completed NCT00049114 Phase 2 doxorubicin hydrochloride;cyclophosphamide;tipifarnib
35 Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Completed NCT00070252 Phase 1, Phase 2 Capecitabine;Docetaxel;Tipifarnib
36 A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer Completed NCT00001193 Phase 2
37 NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Completed NCT00499122 Phase 2 Cyclophosphamide;Docetaxel;Doxorubicin;NOV 002
38 Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer Completed NCT00005800 Phase 2 Docetaxel;Doxorubicin
39 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
40 Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer Completed NCT00004925 Phase 1, Phase 2 pegylated liposomal doxorubicin hydrochloride
41 Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer Completed NCT00450892 Phase 1, Phase 2 docetaxel+lapatinib;docetaxel + trastuzumab;docetaxel + trastuzumab + lapatinib
42 Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer Completed NCT00096343 Phase 2 carboplatin;paclitaxel
43 Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer Completed NCT00005798 Phase 2 Carboplatin;Cyclophosphamide;Thiotepa
44 Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00072319 Phase 2 cyclophosphamide;epirubicin hydrochloride;paclitaxel
45 Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Completed NCT00006110 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
46 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer Completed NCT00856492 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
47 Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer Completed NCT00943410 Phase 2 Herceptin
48 Xeloda (Capecitabine) and External Beam Radiation Completed NCT00916578 Phase 2 Capecitabine
49 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
50 Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer Completed NCT00464646 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Trastuzumab;Bevacizumab

Search NIH Clinical Center for Inflammatory Breast Carcinoma

Cochrane evidence based reviews: inflammatory breast neoplasms

Genetic Tests for Inflammatory Breast Carcinoma

Anatomical Context for Inflammatory Breast Carcinoma

MalaCards organs/tissues related to Inflammatory Breast Carcinoma:

41
Breast, Skin, Prostate, Cervix, Bone, Lung, Lymph Node

Publications for Inflammatory Breast Carcinoma

Articles related to Inflammatory Breast Carcinoma:

(show top 50) (show all 595)
# Title Authors Year
1
Inflammatory Breast Cancer: A Literature Review. ( 30524636 )
2018
2
Characterization of inflammatory breast cancer: a vibrational microspectroscopy and imaging approach at the cellular and tissue level. ( 30468236 )
2018
3
Smartphone-based Compression-Induced Scope with Temperature Sensor for Inflammatory Breast Cancer Screening. ( 30441457 )
2018
4
Immediate breast reconstruction for women having inflammatory breast cancer in the United States. ( 29761885 )
2018
5
Empyema necessitans mimicking inflammatory breast cancer-An unusual case of breast edema. ( 29498446 )
2018
6
In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines. ( 28589573 )
2018
7
Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. ( 28755879 )
2018
8
Interleukin-18 (IL-18) is equally expressed in inflammatory breast cancer and noninflammatory locally advanced breast cancer: A possible association with chemotherapy response. ( 28766916 )
2018
9
Diagnosis of patients with inflammatory breast cancer is a problematic issue. ( 29266196 )
2018
10
Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. ( 29266209 )
2018
11
IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages. ( 29459177 )
2018
12
Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. ( 29460033 )
2018
13
Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. ( 29485045 )
2018
14
Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. ( 29486983 )
2018
15
Reply to Woodward et al.: A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer. ( 29510949 )
2018
16
Development of CNS metastases and survival in patients with inflammatory breast cancer. ( 29579338 )
2018
17
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. ( 29689244 )
2018
18
Inflammatory breast cancer biology: the tumour microenvironment is key. ( 29703913 )
2018
19
Inflammatory breast cancer: The pathologists' perspective. ( 29706301 )
2018
20
Survivorship and Advocacy in Inflammatory Breast Cancer. ( 29721053 )
2018
21
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. ( 29721054 )
2018
22
Dermoscopy of inflammatory breast cancer. ( 29723370 )
2018
23
Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. ( 29729725 )
2018
24
Author Correction: Inflammatory breast cancer biology: the tumour microenvironment is key. ( 29748602 )
2018
25
Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. ( 29768500 )
2018
26
Inflammatory breast cancer-importance of breast imaging. ( 29803530 )
2018
27
Radiation therapy for inflammatory breast cancer. ( 29853159 )
2018
28
The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. ( 29858752 )
2018
29
Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. ( 29858753 )
2018
30
RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis. ( 29874851 )
2018
31
Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. ( 29879283 )
2018
32
CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. ( 29930294 )
2018
33
Locally advanced non-inflammatory breast cancer may be misdiagnosed as inflammatory breast cancer. ( 29941226 )
2018
34
Inflammatory Breast Cancer: Updates on diagnosis and treatment options. ( 29945751 )
2018
35
Inflammatory Breast Cancer: What surgeons need to know. ( 29954638 )
2018
36
The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study. ( 29967698 )
2018
37
Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO). ( 29976157 )
2018
38
Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. ( 30005774 )
2018
39
Analysis of Hierarchical Organization in Gene Expression Networks Reveals Underlying Principles of Collective Tumor Cell Dissemination and Metastatic Aggressiveness of Inflammatory Breast Cancer. ( 30023340 )
2018
40
Inflammatory breast cancer and chest wall disease: The oncologist perspective. ( 30032791 )
2018
41
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. ( 30086764 )
2018
42
Homeoprotein DLX4 expression is increased in inflammatory breast cancer cases from an urban African-American population. ( 30131852 )
2018
43
Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. ( 30248155 )
2018
44
The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review. ( 30278369 )
2018
45
The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome. ( 30288495 )
2018
46
Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? ( 30307616 )
2018
47
Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study. ( 30378451 )
2018
48
Erratum: Zare, A. et al. RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis. Cancers, 2018, 10, 184. ( 30405083 )
2018
49
Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program. ( 30406365 )
2018
50
Diffuse dermal angiomatosis mimicking inflammatory breast carcinoma. ( 28744985 )
2017

Variations for Inflammatory Breast Carcinoma

Expression for Inflammatory Breast Carcinoma

Search GEO for disease gene expression data for Inflammatory Breast Carcinoma.

Pathways for Inflammatory Breast Carcinoma

Pathways related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 CDH1 EGFR ERBB2 ESR1
2 12.45 CDH1 EGFR ERBB2 ESR1
3
Show member pathways
12.38 CDH1 EGFR ERBB2 ESR1
4
Show member pathways
12.22 CDH1 EGFR ERBB2
5
Show member pathways
12.02 CDH1 EGFR ERBB2 ESR1 PGR
6
Show member pathways
12.01 EGFR ERBB2 ESR1
7 11.97 EGFR ERBB2 ESR1
8 11.82 CDH1 EGFR ESR1
9
Show member pathways
11.51 EGFR ERBB2 ESR1
10 11.36 CDH1 EGFR ERBB2
11 11.33 EGFR ERBB2
12 11.29 CDH1 EGFR ERBB2
13 11.25 EGFR ESR1
14 11.2 EGFR ERBB2
15 11.14 CDH1 EGFR
16 11 EGFR ERBB2
17
Show member pathways
10.96 EGFR ERBB2 ESR1 PGR
18 10.82 CDH1 EGFR ERBB2
19 10.76 CDH1 EGFR

GO Terms for Inflammatory Breast Carcinoma

Cellular components related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basal plasma membrane GO:0009925 8.62 EGFR ERBB2

Biological processes related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.83 EGFR ESR1 PGR PROX1
2 positive regulation of transcription, DNA-templated GO:0045893 9.56 CDH1 EGFR ESR1 PROX1
3 cellular response to growth factor stimulus GO:0071363 9.51 EGFR ERBB2
4 positive regulation of fibroblast proliferation GO:0048146 9.49 EGFR ESR1
5 steroid hormone mediated signaling pathway GO:0043401 9.48 ESR1 PGR
6 cellular response to epidermal growth factor stimulus GO:0071364 9.46 EGFR ERBB2
7 cellular response to estradiol stimulus GO:0071392 9.43 EGFR ESR1
8 ERBB2 signaling pathway GO:0038128 9.4 EGFR ERBB2
9 regulation of cell motility GO:2000145 9.37 EGFR ERBB2
10 positive regulation of protein kinase B signaling GO:0051897 9.33 EGFR ERBB2 ESR1
11 regulation of ERK1 and ERK2 cascade GO:0070372 9.32 EGFR ERBB2
12 phosphatidylinositol phosphorylation GO:0046854 9.13 EGFR ERBB2 ESR1
13 negative regulation of ERBB signaling pathway GO:1901185 8.62 EGFR ERBB2

Molecular functions related to Inflammatory Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.61 EGFR ESR1 PGR
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.4 EGFR ERBB2
3 steroid hormone receptor activity GO:0003707 9.37 ESR1 PGR
4 identical protein binding GO:0042802 9.35 CDH1 EGFR ERBB2 ESR1 PGR
5 nuclear receptor activity GO:0004879 9.32 ESR1 PGR
6 steroid binding GO:0005496 9.26 ESR1 PGR
7 nitric-oxide synthase regulator activity GO:0030235 9.16 EGFR ESR1
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.8 EGFR ERBB2 ESR1

Sources for Inflammatory Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....